<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02746237</url>
  </required_header>
  <id_info>
    <org_study_id>KAR5585-101</org_study_id>
    <nct_id>NCT02746237</nct_id>
  </id_info>
  <brief_title>Single and Multiple Ascending Doses Clinical Pharmacology Study With KAR5585</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Phase 1, First-in-human, Single-center, Safety, Tolerability, Ventricular Repolarization and Pharmacokinetic Study of Single and Multiple Ascending Doses of KAR5585 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karos Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Karos Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Safety, tolerability, pharmacokinetics (PK), cardiac conduction and food effect study on&#xD;
      single and multiple ascending doses of KAR5585 in healthy adults.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to explore the safety, tolerability, pharmacokinetics (PK), and&#xD;
      cardiac conduction effects of single and multiple ascending doses of KAR5585 in healthy&#xD;
      adults. Food effect will also be evaluated after a single-dose administration.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with abnormal physical exam results</measure>
    <time_frame>From baseline to 4 days post-dose for single dose and baseline to 6 days post-dose for multiple doses</time_frame>
    <description>Healthy adult volunteers receiving single and multiple doses of KAR5585 administered orally will be monitored for adverse events via physical examination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with abnormal hematology values</measure>
    <time_frame>From baseline to 4 days post-dose for single dose and baseline to 6 days post-dose for multiple doses</time_frame>
    <description>Healthy adult volunteers receiving single and multiple doses of KAR5585 administered orally will be monitored for adverse events via lab evaluation of hematology.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with abnormal electrocardiogram results</measure>
    <time_frame>From baseline to 4 days post-dose for single dose and baseline to 6 days post-dose for multiple doses</time_frame>
    <description>Healthy adult volunteers receiving single and multiple doses of KAR5585 administered orally will be monitored for abnormal ECG results.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with abnormal clinical chemistry values</measure>
    <time_frame>From baseline to 4 days post-dose for single dose and baseline to 6 days post-dose for multiple doses</time_frame>
    <description>Healthy adult volunteers receiving single and multiple doses of KAR5585 administered orally will be monitored for adverse events via lab evaluation of clinical chemistries.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with abnormal urinalysis values</measure>
    <time_frame>From baseline to 4 days post-dose for single dose and baseline to 6 days post-dose for multiple doses</time_frame>
    <description>Healthy adult volunteers receiving single and multiple doses of KAR5585 administered orally will be monitored for adverse events via lab evaluation of urinalysis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma area under the curve (AUC0-24) of prodrug KAR5585 and active inhibitor KAR5417 from time zero to 24 hours after dosing</measure>
    <time_frame>From 0-24 hours on Days 1, 7 and 14</time_frame>
    <description>Assessment of AUC 0-24 hours measured on Day 1, 7 and 14 when drug is dosed without a meal</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach maximum observed plasma concentration (Tmax) of prodrug KAR5585 and active inhibitor KAR5417</measure>
    <time_frame>From 0-24 hours on Days 1, 7 and 14</time_frame>
    <description>Assessment of Tmax measured on Day 1, 7 and 14 when drug is dosed without a meal</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma terminal elimination half- life (T1/2) of prodrug KAR5585 and active inhibitor KAR5417</measure>
    <time_frame>From 0-24 hours on Days 1, 7 and 14</time_frame>
    <description>Assessment of T1/2 measured on Day 1, 7 and 14 when drug is dosed without a meal</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent volume of distribution (Vz/F) of prodrug KAR5585 and active inhibitor KAR5417</measure>
    <time_frame>From 0-24 hours on Days 1, 7 and 14</time_frame>
    <description>Assessment of Vz/F measured on Day 1, 7 and 14 when drug is dosed without a meal</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum peak concentration (Cmax) of prodrug KAR5585 and active inhibitor KAR5417</measure>
    <time_frame>From 0-24 hours on Days 1, 7 and 14</time_frame>
    <description>Assessment of Cmax measured on Day 1, 7 and 14 when drug is dosed without a meal</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum levels of serotonin (ng/mL)</measure>
    <time_frame>Days 1, 7 and 14</time_frame>
    <description>Serum serotonin (5-HT) levels will be measured to evaluate the pharmacodynamic effects of KAR5585 administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary levels of 5-hydroxyindoleacetic acid(mg/24 hrs)</measure>
    <time_frame>From 0-24 hours on Days 1, 7 and 14</time_frame>
    <description>24 hour urine collection with analysis for 5-HIAA (5-hydroxyindoleacetic acid) levels.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary levels of creatinine (gm/24 hrs)</measure>
    <time_frame>From 0-24 hours on Days 1, 7 and 14</time_frame>
    <description>24 hour urine collection with analysis for creatinine levels.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary levels of 5-hydroxyindoleacetic acid normalized to creatinine (mg/gm)</measure>
    <time_frame>From 0-24 hours on Days 1, 7 and 14</time_frame>
    <description>24 hour urine collection with analysis for 5-HIAA (5-hydroxyindoleacetic acid). Urinary creatinine will be used to normalize urinary 5-HIAA levels: urinary 5-HIAA mg/gm creatinine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma levels of 5-hydroxyindoleacetic acid (ng/mL)</measure>
    <time_frame>Days 1, 7 and 14</time_frame>
    <description>Plasma 5-HIAA (5-hydroxyindoleacetic acid) levels will be measured to evaluate the pharmacodynamic effects of KAR5585 administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma area under the curve (AUC0-24) of prodrug KAR5585 and active inhibitor KAR5417 from time zero to 24 hours after dosing</measure>
    <time_frame>From 0-24hrs on Days 1, 7 and 14</time_frame>
    <description>To determine the effect of food intake on the pharmacokinetics of KAR5585 and its active metabolite KAR5417, a cohort of patients will be studied after a single dose given fasting, followed by the same dose given with a high fat content food.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach maximum observed plasma concentration (Tmax) of prodrug KAR5585 and active inhibitor KAR5417</measure>
    <time_frame>From 0-24hrs on Days 1, 7 and 14</time_frame>
    <description>To determine the effect of food intake on the pharmacokinetics of KAR5585 and its active metabolite KAR5417, a cohort of patients will be studied after a single dose given fasting, followed by the same dose given with a high fat content food.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma terminal elimination half-life (T1/2) of prodrug KAR5585 and active inhibitor KAR5417</measure>
    <time_frame>From 0-24hrs on Days 1, 7 and 14</time_frame>
    <description>To determine the effect of food intake on the pharmacokinetics of KAR5585 and its active metabolite KAR5417, a cohort of patients will be studied after a single dose given fasting, followed by the same dose given with a high fat content food.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent volume of distribution (Vz/F) of prodrug KAR5585 and active inhibitor KAR5417</measure>
    <time_frame>From 0-24hrs on Days 1, 7 and 14</time_frame>
    <description>To determine the effect of food intake on the pharmacokinetics of KAR5585 and its active metabolite KAR5417, a cohort of patients will be studied after a single dose given fasting, followed by the same dose given with a high fat content food.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum peak concentration (Cmax) of prodrug KAR5585 and active inhibitor KAR5417</measure>
    <time_frame>From 0-24hrs on Days 1, 7 and 14</time_frame>
    <description>To determine the effect of food intake on the pharmacokinetics of KAR5585 and its active metabolite KAR5417, a cohort of patients will be studied after a single dose given fasting, followed by the same dose given with a high fat content food.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Pulmonary Arterial Hypertension</condition>
  <arm_group>
    <arm_group_label>KAR5585</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>KAR5585 Capsules</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo capsules</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KAR5585 Capsules</intervention_name>
    <description>Single and multiple ascending doses of KAR5585 (100 mg initial dose)</description>
    <arm_group_label>KAR5585</arm_group_label>
    <other_name>KAR5585</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Capsules</intervention_name>
    <description>Single and multiple ascending doses of placebo (100 mg initial dose)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject is able to read, write, and comprehend English at a sufficient level to&#xD;
             understand study-related materials&#xD;
&#xD;
          -  Subject is able to provide written informed consent and to comply with all study&#xD;
             requirements and restrictions&#xD;
&#xD;
          -  Subject is male or female and aged 18 to 65 years, inclusive, at the time of informed&#xD;
             consent&#xD;
&#xD;
          -  Subject is in good health as determined by the PI based on detailed medical history,&#xD;
             physical examination, vital signs, clinical laboratory tests, ECGs, and other pre-dose&#xD;
             evaluations&#xD;
&#xD;
          -  Subject agrees to use a medically acceptable form of birth control from CRU admission&#xD;
             until at least 30 days (female subject) or 90 days (male subject) after the last dose&#xD;
             of study drug. Males will also not donate sperm from CRU admission until at least 90&#xD;
             days after the last dose of study drug. If a subject is not sexually active but&#xD;
             becomes active during study participation, the subject agrees they and their partner&#xD;
             will use a medically accepted form of contraception for the time specified. Medically&#xD;
             acceptable forms of contraception are:&#xD;
&#xD;
               -  FDA-approved female hormonal contraceptives used consistently for 2 or more&#xD;
                  cycles before Screening, including oral contraceptives, intrauterine device&#xD;
                  (IUD), medroxyprogesterone acetate injection (Depo Provera®), hormonal implant&#xD;
                  (Norplant®, Implanon®, Nexplanon®), and vaginal ring (NuvaRing®)&#xD;
&#xD;
               -  Male condom plus spermicide&#xD;
&#xD;
               -  Male condom plus contraceptive sponge, foam, or jelly&#xD;
&#xD;
               -  Female condom plus spermicide&#xD;
&#xD;
               -  Diaphragm with spermicide plus male condom&#xD;
&#xD;
               -  Cervical cap with spermicide plus male condom&#xD;
&#xD;
               -  Surgical sterilization of the subject or partner (vasectomy for males,&#xD;
                  hysterectomy or bilateral oophorectomy for females)&#xD;
&#xD;
               -  Abstinence&#xD;
&#xD;
          -  If female, subject agrees that a serum pregnancy test ([β hCG] beta human chorionic&#xD;
             gonadotropin ) will be performed at Screening, on Day 2 (CRU admission), and at the&#xD;
             last study visit and negative test results at Screening and CRU admission are required&#xD;
             to be considered for study participation&#xD;
&#xD;
          -  Subject has a body mass index (BMI) of 20 to 35 kg/m2, inclusive, and body weight &lt;&#xD;
             120 kg at Screening&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject currently uses tobacco or nicotine-containing products or has used such&#xD;
             products within 6 months before CRU admission&#xD;
&#xD;
          -  Subject has history or current evidence of any clinically significant cardiac,&#xD;
             endocrinologic, hematologic, hepatobiliary, immunologic, metabolic, urologic,&#xD;
             pulmonary, neurologic, dermatologic, psychiatric, renal, or other major disease, as&#xD;
             determined by the PI&#xD;
&#xD;
          -  Subject has a history of cancer within 5 years before CRU admission (excluding&#xD;
             non-melanoma skin cancer)&#xD;
&#xD;
          -  Subject has a history of autonomic dysfunction (eg, history of repeated dizziness,&#xD;
             fainting, or symptomatic orthostatic hypotension)&#xD;
&#xD;
          -  Subject has a history of risk factors for torsades de pointes, including unexplained&#xD;
             syncope, known long QT syndrome, heart failure, myocardial infarction, angina, OR&#xD;
             clinically significant abnormal laboratory assessments including hypokalemia,&#xD;
             hypomagnesemia, or hypercalcemia OR has a family history of long QT syndrome or&#xD;
             Brugada syndrome&#xD;
&#xD;
          -  Subject has 1 or more clinically significant abnormal laboratory test values (as&#xD;
             determined by the PI)&#xD;
&#xD;
          -  Subject has an uninterpretable or abnormal screening ECG indicating a second- or&#xD;
             third-degree atrioventricular block, or 1 or more of the following: QRS interval&#xD;
             (ventricular depolarization) &gt; 110 msec; a PR interval (atrioventricular conduction) &gt;&#xD;
             220 msec, or QTc (corrected QT interval) of ≥ 450 msec (for male) or ≥ 470 msec (for&#xD;
             female) or any rhythm other than sinus rhythm that is interpreted by the PI or a&#xD;
             qualified designee to be clinically significant&#xD;
&#xD;
          -  Subject has a resting heart rate (HR) of &lt; 40 beats/min or &gt; 90 beats/min at Screening&#xD;
             or on CRU admission&#xD;
&#xD;
          -  Subject has a sustained supine systolic blood pressure (BP) &gt; 155 or &lt; 90 mm Hg or a&#xD;
             supine diastolic BP &gt; 95 or &lt; 50 mm Hg at Screening or upon CRU admission. Blood&#xD;
             pressure in the supine position may be retested once and 'sustained' is defined as the&#xD;
             parameter (either systolic or diastolic BP) being outside the stated limits at both&#xD;
             assessments.&#xD;
&#xD;
          -  Subject participates in another clinical trial or treatment with an investigational&#xD;
             agent within 30 days or 5 half-lives, whichever is longer, before CRU admission&#xD;
&#xD;
          -  Subject has a history of alcohol or drug abuse or dependence within 12 months before&#xD;
             CRU admission, as determined by the PI&#xD;
&#xD;
          -  Subject has a clinically significant infection within 3 months before CRU admission,&#xD;
             as determined by the PI&#xD;
&#xD;
          -  Subject has any condition that, in the opinion of the PI, would make the subject&#xD;
             unsuitable for enrollment or could interfere with the subject's participation in or&#xD;
             completion of the study&#xD;
&#xD;
          -  Subject has a positive urine screen for prohibited drugs (cocaine, cannabinoids,&#xD;
             nicotine [urine cotinine is the detection mechanism for nicotine], opiates,&#xD;
             barbiturates, amphetamines, and benzodiazepines) or positive urine test for alcohol&#xD;
&#xD;
          -  Subject has a positive blood screen for human immunodeficiency virus, hepatitis B&#xD;
             surface antigen, or hepatitis C virus antibody at the Screening Visit&#xD;
&#xD;
          -  Subject has had a known or suspected hypersensitivity or idiosyncratic reaction to the&#xD;
             cellulose used in the placebo to be used in this study&#xD;
&#xD;
          -  Subject has donated blood or any blood products within 3 months before Screening or&#xD;
             plans to donate blood during or within 3 months after study completion&#xD;
&#xD;
          -  Subject consumes an excessive amount of caffeine daily, defined as &gt; 4 cups of coffee&#xD;
             or equivalent per day. Subjects will abstain from caffeine consumption for 48 hours&#xD;
             before dosing and while confined to the CRU.&#xD;
&#xD;
          -  Subject has consumed or will consume any concomitant therapy; prescription or&#xD;
             over-the-counter (OTC) medication; or nutritional, herbal, or vitamin supplements&#xD;
             other than contraceptives (eg, oral, systemic) and ibuprofen (only if needed, maximum&#xD;
             2.4 g/day) from 14 days or 5 half-lives (whichever is longer) before dosing and while&#xD;
             confined to the CRU&#xD;
&#xD;
          -  For Part 2 only: Subject has consumed any food, juice, beverage, or medication&#xD;
             (prescription or non-prescription) containing acetaminophen, alcohol, avocado, banana,&#xD;
             caffeine, eggplant, kiwi fruit, nut (hickory nut, pecan, walnut), pineapple, plum, or&#xD;
             tomato products within 48 hours before CRU admission&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carlos Sanabria, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Spaulding Clinical</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Spaulding Clinical</name>
      <address>
        <city>West Bend</city>
        <state>Wisconsin</state>
        <zip>53095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <study_first_submitted>March 18, 2016</study_first_submitted>
  <study_first_submitted_qc>April 20, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 21, 2016</study_first_posted>
  <last_update_submitted>August 29, 2016</last_update_submitted>
  <last_update_submitted_qc>August 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 30, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Serotonin</keyword>
  <keyword>Pulmonary Arterial Hypertension</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Phase 1</keyword>
  <keyword>Healthy Volunteers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Arterial Hypertension</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

